Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Taxotere vs AC in Breast Cancer (TACAC)
NCT00206518Phase 2Completed
- Sponsor
- Mothaffar Rimawi
- Start
- Sep 2004
- Primary completion
- Oct 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Taxotere/Docetaxel with AC Adriamycin/Cytoxan (2 arms). Primary endpoint: Pathological Tumor Response to Neoadjuvant Chemotherapy at 10 years. Started Sep 2004; status: completed.
02
Drugs
docetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00206518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206518.